During the past decade, Medizinische Universitatsklinik Innsbruck conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Medizinische Universitatsklinik Innsbruck" are "Chronic Lymphocytic Leukemia" (1 trials), "Multiple Myeloma" (1 trials) and "Small Lymphocytic Lymphoma" (1 trials). Many other conditions were trialed in "Medizinische Universitatsklinik Innsbruck" in a lesser frequency.

Most popular intervention types in "Medizinische Universitatsklinik Innsbruck" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bendamustine" (1 trials), "Bortezomib" (1 trials), "Cilta-cel" (1 trials), "Cyclophosphamide" (1 trials) and "Dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Medizinische Universitatsklinik Innsbruck" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Medizinische Universitatsklinik Innsbruck". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Medizinische Universitatsklinik Innsbruck, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Medizinische Universitatsklinik Innsbruck, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".